Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1845259 | 0.93 | POLB (0.51) | HTTMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6756946 | 0.81 | FGFR1 (0.50) | MAPTKMT2AMEN1ACHECYP2E1 | |
| SCHEMBL22465893 | 0.80 | HTR2A (0.42) | HTTMAPTCYP1A2KMT2AMEN1 | |
| SCHEMBL16687191 | 0.80 | MAPT (0.51) | MAPTCYP1A2CYP2C9KMT2AMEN1 | |
| SCHEMBL30269973 | 0.80 | MAPT (0.50) | MAPTCYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL27603213 | 0.80 | MEN1 (0.43) | HTTMAPTKMT2AMEN1ACHE | |
| SCHEMBL28369711 | 0.80 | MAPT (0.50) | MAPTCYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL15442510 | 0.79 | TSHR (0.50) | MAPTCYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL9699641 | 0.78 | HPGD (0.51) | MAPTCYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL1616767 | 0.78 | ALDH1A1 (0.49) | MAPTCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771378-B2 | Fused morpholinopyrimidines and methods of use thereof | DENALI THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. | 2017-02-16 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2496558-B1 | TETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-0991625-B1 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-06-01 | — | — | EP | disclosed |
| US-6602895-B2 | Inhibitors of factor Xa with a neutral P1 specificity group | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | GALEMMO ROBERT A (US) | 2003-05-15 | — | — | US | disclosed |
| US-6403620-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | disclosed |
| EP-0991625-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5998424-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998057937-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044182-A1 | FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF | SMN1; SMN2, FUS, SYNCRIP | HTT 4/4885MAPT 39/4885CYP1A2 4525/4885 |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTT 3114/4885MAPT 4254/4885CYP1A2 1641/4885 |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | F12, F11, SERPINC1 | HTT 4334/4885MAPT 4818/4885CYP1A2 995/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | HTT 3114/4885MAPT 4254/4885CYP1A2 1641/4885 |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | APP, BACE1, BACE2 | HTT 106/4885MAPT 229/4885CYP1A2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.